Alvotech Appoints Sarah Tanksley as Chief Quality Officer

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) announced the appointment of Sarah Tanksley as its new Chief Quality Officer, effective October 14. She succeeds Reem Malki, who stepped down for personal reasons. Tanksley, having previously consulted for Alvotech, brings over 20 years of experience from regulatory agencies like the FDA and the NIH. Her expertise in regulatory compliance and GMP is expected to facilitate a smooth transition and enhance Alvotech's capabilities.

Alvotech focuses on developing biosimilar medicines to serve patients globally.

Positive

• Sarah Tanksley's extensive experience in regulatory affairs and compliance strengthens leadership.
• Her previous consultancy role allows for a smoother transition.

Negative

• Reem Malki's departure may raise concerns about continuity in leadership.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corporate leadership team as Chief Quality Officer, effective October 14.  Ms. Tanksley succeeds Reem Malki, who is stepping down for personal reasons.

“Sarah has been actively working with Alvotech as a consultant and we are very pleased that she will join our team in this new capacity,” said Mark Levick, Chief Executive Officer of Alvotech. “Her familiarity with our operation facilitates a smooth transition and we are excited to benefit further from her experience in regulatory compliance and GMP.  Sarah brings strong capabilities to the role of Chief Quality Officer, having excelled in regulatory agency roles as well as a respected industry practitioner. I also want to thank Reem for her vital contribution to the Alvotech team, as we built a world-class biosimilars development and manufacturing platform and achieved successful market launches of our first biosimilar in both Europe and Canada.”

Ms. Tanksley has 20 years of experience within the U.S. National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and as an industry consultant. She teaches graduate courses in GMP compliance and Regulatory Affairs as an Adjunct Professor in the Graduate Biochemistry and Molecular Biology Program at Georgetown University School of Medicine and with the Advanced Academic Program at Johns Hopkins University. Sarah has an MS degree in Bioscience Regulatory Affairs from Johns Hopkins University, as well as an MS degree in Biochemistry and Molecular Biology from Georgetown University School of Medicine.

About Alvotech

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

CONTACTS

Alvotech Investor Relations and Global Communication
Benedikt Stefansson
alvotech.ir[at]alvotech.com

FAQ

What is the significance of Sarah Tanksley's appointment at Alvotech?

Sarah Tanksley's appointment is significant as she brings extensive regulatory experience, aiming to enhance Alvotech's quality and compliance operations in biosimilar development.

Why did Reem Malki step down from her position at Alvotech?

Reem Malki stepped down for personal reasons, which could impact the continuity of leadership at Alvotech.

When will Sarah Tanksley officially start her role at Alvotech?

Sarah Tanksley will officially start her role as Chief Quality Officer on October 14.

What experience does Sarah Tanksley bring to Alvotech?

Sarah Tanksley brings over 20 years of experience, including roles at the FDA and NIH, along with a strong background in regulatory compliance and GMP.

How might Sarah Tanksley's leadership impact Alvotech's future?

With her expertise, Sarah Tanksley is expected to strengthen Alvotech's regulatory processes and facilitate successful biosimilar development and market launches.